natgillin/translations-raw huggingface dataset:
The post-dose 2 geometric mean titres (GMTs) against mumps and rubella were comparable across all age categories, while the GMTs against measles were lower in subjects who received the first dose at 9 months of age as compared to subjects who received the first dose at 11 or 12 months of age. 
Geometrična povprečja titrov (GMT - geometric mean titers) proti mumpsu in rdečkam so bila po 2. odmerku primerljiva za vse starostne skupine, medtem ko so bila GMT proti ošpicam nižja pri osebah, ki so prvi odmerek prejele v starosti 9 mesecev, v primerjavi z osebami, ki so prvi odmerek prejele v starosti 11 ali 12 mesecev.
Marketing Authorisation Holder: MSD VACCINS, 162 avenue Jean Jaurès, 69007 Lyon, France 
Imetnik dovoljenja za promet z zdravilom: MSD VACCINS, 162 avenue Jean Jaurès, 69007 Lyon, Francija
M-M-RVAXPRO is expected to have no or negligible influence on ability to drive and use machines. 
Pri cepivu M-M-RVAXPRO se pričakuje, da nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
• An illness consisting of muscle weakness, abnormal sensations, tingling in the arms, legs, and upper body (Guillain-Barré syndrome). 
• bolezen, ki zajema šibkost mišic, nenormalne občutke, mravljinčenje v rokah, nogah in zgornjem delu telesa (GuillainBarréjev sindrom)
Infants from 9 to 12 months of age vaccinated with a measles-containing vaccine during measles outbreaks or for other reasons may fail to respond to the vaccine due to the presence of circulating antibodies of maternal origin and/or immaturity of the immune system (see sections 4.2 and 5.1). 
Pri dojenčkih, starih od 9 do 12 mesecev, ki so zaradi izbruha ošpic ali drugih razlogov cepljeni s cepivom, ki vsebuje virus ošpic, lahko zaradi prisotnosti materinih protiteles v obtoku in/ali nezrelosti imunskega sistema ne pride do odziva na cepivo (glejte poglavji 4.2 in 5.1).
IM or SC use 
ali s.c. uporaba
Valence (seropro tection level) 
Valenca (stopnja serozaščite
Due caution should be employed in administration of M-M-RVAXPRO to persons with individual or family history of convulsions, or a history of cerebral injury. 
Ustrezna previdnost je potrebna, kadar s cepivom M-M-RVAXPRO cepimo osebe z osebno ali družinsko anamnezo konvulzij ali anamnezo poškodbe možganov.
Do not freeze the vaccine. 
Cepiva ne zamrzujte.
Dose 1 at 11 months / Dose 2 at 14 months N = 480 
1. odmerek pri 11 mesecih / 2. odmerek pri 14 mesecih N = 480
A second dose may be administered at least 4 weeks after the first dose in accordance with official recommendation. 
V skladu z uradnimi priporočili se lahko cepi še z drugim odmerkom najmanj 4 tedne po prvem cepljenju.
Keep the vial of powder in the outer carton in order to protect from light. 
Vialo s praškom shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
The seroprotection rates to measles, mumps, and rubella for the Full Analysis Set are given in Table 1. 
Stopnje serozaščite proti ošpicam, mumpsu in rdečkam so podane za popolno analizo v preglednici 1.
When completely reconstituted, the vaccine is a clear yellow liquid. 
Po končani pripravi je cepivo bistra rumena tekočina.
Also, if the person who is to be vaccinated has already been exposed to the measles, mumps, or rubella virus but is not yet ill, M-M-RVAXPRO may not be able to prevent the illness from appearing. 
Če je bila oseba, ki bo cepljena, že izpostavljena virusu ošpic, mumpsa ali rdečk, ni pa še zbolela, cepivo M-M-RVAXPRO morda ne bo moglo preprečiti pojava bolezni.
It is recommended that the vaccine be administered immediately after reconstitution or stored in the refrigerator and used within 8 hours to minimize loss of potency. 
Priporočamo, da cepivo uporabite takoj po pripravi ali da ga shranite v hladilniku in uporabite v 8 urah, da se izognete izgubi učinkovitosti.
Severe humoral or cellular (primary or acquired) immunodeficiency, e.g. severe combined immunodeficiency, agammaglobulinemia and AIDS or symptomatic HIV infection or an age-specific CD4+ T-lymphocyte percentage in children below 12 months: CD4+ <25% ; children between 12-35 months: CD4+ < 20%; children between 36-59 months: CD4+ < 15% (see section 4.4). 
Huda humoralna ali celična (primarna ali pridobljena) imunska pomanjkljivost, npr. huda kombinirana imunska pomanjkljivost, agamaglobulinemija in AIDS ali simptomatska okužba s HIV ali za starost specifični odstotek CD4+ T-limfocitov pri otrocih do 12 mesecev: CD4+ < 25 %; pri otrocih med 12 in 35 meseci: CD4+ < 20 %; pri otrocih med 36 in 59 meseci: CD4+ < 15 % (glejte poglavje 4.4).
Vaccination of susceptible non-pregnant adolescent and adult females of childbearing age with live attenuated rubella virus vaccine is indicated if certain precautions are observed (see sections 4.4 and 4.6). 
Cepljenje dovzetnih mladostnic in odraslih žensk v rodni dobi, ki niso noseče, z oslabljenim živim cepivom proti rdečkam je indicirano ob upoštevanju nekaterih previdnostnih ukrepov (glejte poglavji 4.4 in 4.6).
On the basis of the scientific conclusions for measles / mumps / rubella vaccines (live, attenuated) the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing measles / mumps / rubella vaccines (live, attenuated) is unchanged subject to the proposed changes to the product information 
Na podlagi znanstvenih zaključkov za cepiva proti ošpicam / mumpsu / rdečkam (živa, oslabljena) odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) cepiva proti ošpicam / mumpsu / rdečkam (živa, oslabljena) nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
Dose 1 at 12 months / Dose 2 at 15 months N = 466 
1. odmerek pri 12 mesecih / 2. odmerek pri 15 mesecih N = 466
M-M-RVAXPRO can be administered to infants from 9 months of age under special circumstances (see sections 4.2, 4.4 and 5.1). 
S cepivom M-M-RVAXPRO se lahko v posebnih primerih cepi dojenčke, starejše od 9 mesecev (glejte poglavja 4.2, 4.4 in 5.1).
History of hypersensitivity to any measles, mumps, or rubella vaccine, or to any of the excipients, including neomycin (see sections 2, 4.4, and 6.1). 
Preobčutljivost v anamnezi na katero koli cepivo proti ošpicam, mumpsu ali rdečkam ali katero koli pomožno snov, vključno z neomicinom (glejte poglavja 2, 4.4 in 6.1).
PostDose 1 PostDose 2 
Po 1. odmerku Po 2. odmerku
Individuals who require vaccination against measles can receive M-M-RVAXPRO regardless of their immune status to mumps or rubella if a monovalent measles vaccine is not readily available. 
Posamezniki, ki jih je treba cepiti proti ošpicam, lahko prejmejo cepivo M-M-RVAXPRO ne glede na njihovo stanje imunosti proti mumpsu ali rdečkam, če enovalentnega cepiva proti ošpicam ni takoj na voljo.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 
Neuporabljeno cepivo ali odpadni material je treba zavreči v skladu z lokalnimi predpisi.
A comparative study in 752 subjects who received M-M-RVAXPRO either by intramuscular route or subcutaneous route demonstrated a similar immunogenicity profile between both administration routes. 
Primerjalna študija pri 752 osebah, ki so prejele cepivo M-M-RVAXPRO intramuskularno ali subkutano, je pokazala, da je profil imunogenosti pri obeh načinih apliciranja podoben.
M-M-RVAXPRO is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals from 12 months of age (see section 4.2). 
Cepivo M-M-RVAXPRO je indicirano za sočasno cepljenje proti ošpicam, mumpsu in rdečkam v starosti od 12 mesecev dalje (glejte poglavje 4.2).
However, M-M-RVAXPRO may not always be able to prevent measles developing in these cases. 
Vendar pa cepivo M-M-RVAXPRO v teh primerih ne more vedno preprečiti pojava ošpic.
• Aseptic meningitis (fever, feeling sick, vomiting, headache, stiff neck, and sensitivity to light); swollen testicles; infection of the middle ear; inflamed salivary glands; atypical measles (described in patients who received a killed measles virus vaccine, usually given before 1975). 
• aseptični meningitis (zvišana telesna temperatura, slabost, bruhanje, glavobol, trd vrat in občutljivost na svetlobo), otekla moda, okužba srednjega ušesa, vnete žleze slinavke, atipične ošpice (opisano pri bolnikih, ki so prejeli cepivo z mrtvim virusom ošpic, večinoma pred letom 1975)
Administration of immune globulins concomitantly with M-M-RVAXPRO may interfere with the expected immune response. 
Dajanje imunoglobulinov sočasno s cepivom M-M-RVAXPRO lahko ovira pričakovani imunski odziv.
M-M-RVAXPRO is to be used on the basis of official recommendations. 
Cepljenje s cepivom M-M-RVAXPRO je treba izvajati v skladu z uradnimi priporočili.
• Headache; fainting; nerve disorders which can cause weakness, tingling, or numbness; eye nerve disturbances. 
• glavobol, omedlevica, bolezni živcev, ki lahko povzročijo šibkost, mravljinčenje ali odrevenelost, motnje vidnega živca
In addition and as previously underlined from the first of June 2010 until the fifth of February 2016, the Dutch Pharmacovigilance Center (Lareb) received 327 reports of MedDRA® Preferred Term (PT) ‘Crying' (preferred term) following immunization with the MMR vaccine. 
Poleg tega so na nizozemskem centru za farmakovigilanco (Lareb), v obdobju od 1. junija 2010 do 5. februarja 2016, prejeli 327 poročil z MedDRA® prednostnim izrazom "jok" po imunizaciji s cepivom MMR (cepivo proti ošpicam, mumpsu in rdečkam).
Cases of aseptic meningitis have been reported following measles, mumps, and rubella vaccination. 
O primerih aseptičnega meningitisa so poročali po cepljenju proti ošpicam, mumpsu in rdečkam.
Children under treatment for tuberculosis have not experienced exacerbation of the disease when immunized with live measles virus vaccine. 
Pri otrocih, ki so se zdravili zaradi tuberkuloze, po cepljenju z živim cepivom proti ošpicam ni prišlo do poslabšanja bolezni.
As with other vaccines, M-M-RVAXPRO may not completely protect all persons who are vaccinated. 
Tako kot druga cepiva tudi cepivo M-M-RVAXPRO ne pomeni popolne zaščite vseh cepljenih oseb.
There have been reports of SSPE in children who did not have a history of infection with wild-type measles but did receive measles vaccine. 
Poročali so o SSPE pri otrocih brez anamneze okužbe z divjim sevom ošpic, ki pa so bili cepljeni proti ošpicam.
For storage conditions after the reconstitution of the medicinal product, see section 6.3 
Za pogoje shranjevanja po rekonstituciji cepiva glejte poglavje 6.3.
Fertility M-M-RVAXPRO has not been evaluated in fertility studies. 
Plodnost Cepiva M-M-RVAXPRO niso ovrednotili v študijah plodnosti.
M-M-RVAXPRO may be given with Prevenar and/or hepatitis A vaccine at the same visit at a separate injection site (e.g. the other arm or leg). 
Cepivo M-M-RVAXPRO se lahko da sočasno s cepivom Prevenar in/ali cepivom proti hepatitisu A, toda na drugo vbodno mesto (npr. na drugo roko ali nogo).
Since live measles vaccine and live mumps vaccine are produced in chick embryo cell culture, persons with a history of anaphylactic, anaphylactoid, or other immediate reactions (e.g., hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions. 
Ker sta živo cepivo proti ošpicam in živo cepivo proti mumpsu pridobljeni iz celičnih kultur piščančjih zarodkov, so lahko osebe z anamnezo anafilaktične, anafilaktoidne ali druge takojšnje reakcije (npr. koprivnica, oteklina ust in grla, težave pri dihanju, hipotenzija ali šok) po zaužitju jajc izpostavljene večjemu tveganju za takojšnje preobčutljivostne reakcije.
Vaccinating susceptible postpubertal females confers individual protection against subsequently acquiring rubella infection during pregnancy, which, in turn, prevents infection of the foetus and consequent congenital rubella injury. 
Cepljenje dovzetnih žensk po puberteti daje individualno zaščito pred prihodnjo okužbo z rdečkami v nosečnosti, kar preprečuje tudi okužbo ploda in posledično prirojene poškodbe zaradi rdečk.
It has been reported that live attenuated measles, mumps, and rubella virus vaccines given individually may result in a temporary depression of tuberculin skin sensitivity. 
Poročali so, da lahko oslabljena živa cepiva proti ošpicam, mumpsu in rdečkam, aplicirana posamezno, začasno zmanjšajo kožno občutljivost na tuberkulin.
Among these children, the vaccine-related adverse reactions, summarised in section b, were observed in individuals following vaccination with M-M-RVAXPRO (excluding isolated reports with frequency <0.2%). 
Med temi otroci so po cepljenju s cepivom M-M-RVAXPRO opazili s cepljenjem povezane neželene učinke, ki so povzeti v poglavju b (brez posameznih poročil o neželenih učinkih s pojavnostjo < 0,2 %).
Studies have shown that breast-feeding postpartum women vaccinated with live attenuated rubella vaccines may secrete the virus in breast milk and transmit it to breast-fed infants. 
Študije so pokazale, da se lahko pri doječih materah, ki so bile po porodu cepljene z živim oslabljenim cepivom proti rdečkam, virus izloča v mleko in se prenese na dojenčke.
After reconstitution,1 dose (0.5 ml) contains: Measles virus Enders' Edmonston strain (live attenuated) 
Po pripravi cepiva 1 odmerek (0,5 ml) vsebuje: Virus ošpic, sev Enders' Edmonston (živ, oslabljen)
Not known see section c c. Description of selected adverse reactions 
Žilne bolezni vaskulitis neznana pogostnost glejte poglavje c c. Opis posameznih neželenih učinkov
In the Full Analysis Set (vaccinated subjects regardless of their antibody titre at baseline), high seroprotection rates of >99% were elicited to mumps and rubella post-dose 2, regardless of the age of the vaccinee at the first dose. 
V popolni analizi (cepljenih oseb, ne glede na njihov izhodiščni titer protiteles) so bile proti mumpsu in rdečkam po 2. odmerku dosežene visoke stopnje serozaščite > 99 % ne glede na starost posameznika ob prejetju prvega odmerka.
These studies also established that seroconversion in response to vaccination against measles, mumps, and rubella paralleled protection from these diseases. 
V teh študijah je bila serokonverzija kot odziv na cepljenje proti ošpicam, mumpsu in rdečkam vzporedna zaščiti po vsaki od teh prebolelih bolezni.
Family history of congenital or hereditary immunodeficiency, unless the immune competence of the potential vaccine recipient is demonstrated. 
Družinska anamneza prirojene ali dedne imunske pomanjkljivosti, razen če je dokazana imunska sposobnost osebe, ki naj bi bila cepljena.
What you need to know before you receive M-M-RVAXPRO 
Kaj morate vedeti, preden boste prejeli cepivo M-M-RVAXPRO
What M-M-RVAXPRO is and what it is used for 
Kaj je cepivo M-M-RVAXPRO in za kaj ga uporabljamo
Common (may affect 1 to 10 in 100 vaccinees) 
Pogosti (pojavijo se lahko pri 1 do 10 od 100 cepljenih oseb)
The doctor may delay vaccination for at least 3 months following blood or plasma transfusions, or immune globulin (known as IG). 
Zdravnik lahko odloži cepljenje za vsaj 3 mesece po transfuziji krvi ali plazme ali po prejemu imunoglobulinov.
The potential risk-to-benefit ratio should be carefully evaluated before considering vaccination in such cases. 
V takšnih primerih je treba pred odločitvijo za cepljenje skrbno ovrednotiti razmerje med morebitnim tveganjem in koristjo cepljenja.
In addition, individuals who experienced thrombocytopenia with the first dose of M-M-RVAXPRO (or its component vaccines) may develop thrombocytopenia with repeat doses. 
Poleg tega se lahko pri posameznikih, pri katerih se je trombocitopenija pojavila po prvem cepljenju s cepivom M-M-RVAXPRO (ali s cepivi, ki ga sestavljajo), trombocitopenija pojavi po ponovnih odmerkih.
• Joint pain and/or swelling (usually transient and rarely chronic); muscle pain. 
• bolečina v sklepih in/ali otekanje sklepov (običajno prehodno in redko kronično), bolečine v mišicah
Only rarely have vaccine recipients developed chronic joint symptoms. 
Le redko so se pri cepljenih osebah pojavili kronični simptomi v sklepih.
When a person is given the vaccine, the immune system (the body's natural defences) will make antibodies against the measles, mumps, and rubella viruses. 
Po cepljenju začne imunski sistem (naravna obramba telesa) izdelovati protitelesa proti virusom ošpic, mumpsa in rdečk.
There are no reports of transmission of the more attenuated Enders' Edmonston strain of measles virus or the Jeryl Lynn™ strain of mumps virus from vaccinees to susceptible contacts. 
Ni poročil o prenosu bolj oslabljenega virusa ošpic seva Enders' Edmonston ali virusa mumpsa seva Jeryl Lynn™ s cepljenih posameznikov na kontaktne osebe, dovzetne za okužbo z virusom ošpic ali mumpsa.
Detailed information on this vaccine is available on the European Medicines Agency website: http://www.ema.europa.eu. 
Podrobne informacije o cepivu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
• Inflammation of blood vessels. 
• vnetje krvnih žil
Pregnancy should be avoided for 1 month following vaccination. 
Ženska 1 mesec po cepljenju ne sme zanositi.
M-M-RVAXPRO is given to help protect you or your child against measles, mumps, and rubella. 
Cepljenje s cepivom M-M-RVAXPRO pomaga zaščititi vas ali vašega otroka pred ošpicami, mumpsom in rdečkami.
• Discharge and itching of the eyes with crusting of eyelids (conjunctivitis). 
• izcedek iz oči in srbenje oči s krmežljavčki (zaspančki) na vekah (konjunktivitis)
If you have been told by your doctor that you or your child have an intolerance to some sugars, inform your doctor before you or your child receive this vaccine. 
Če vam je zdravnik povedal, da vi ali vaš otrok ne prenašate nekaterih sladkorjev, se pred cepljenjem s tem cepivom posvetujte s svojim zdravnikom.
M-M-RVAXPRO can be administered to infants from 9 to 12 months of age under special circumstances. 
S cepivom M-M-RVAXPRO se lahko v posebnih primerih cepi dojenčke, stare od 9 do 12 mesecev.
The solvent is a clear colourless liquid. 
Vehikel je bistra brezbarvna tekočina.
Females of child-bearing age should take the necessary precautions to avoid pregnancy for 1 month, or according to doctor's recommendation, after they have been given the vaccine. 
Ženske v rodni dobi morajo 1 mesec po cepljenju, oziroma po navodilu zdravnika, ustrezno poskrbeti, da ne zanosijo.
In adolescent girls, the reactions appear to be intermediate in incidence between those seen in children and adult women. 
Pri dekletih v adolescenci so neželeni učinki po pojavnosti vmes med neželenimi učinki pri otrocih in neželenimi učinki pri odraslih ženskah.
†, Febrile convulsion (in children), Guillain-Barre syndrome, Headache, Measles inclusion body encephalitis (MIBE) (see section 4.3), Ocular palsies, Optic neuritis, Paraesthesia, Polyneuritis, Polyneuropathy, Retrobulbar neuritis, Syncope 
†, vročinski krči (pri otrocih), Guillain-Barréjev sindrom, glavobol, ošpični encefalitis z inkluzijskimi telesci (MIBE»measles inclusion body encephalitis«) (glejte poglavje 4.3), očesne paralize, optični nevritis, parestezija, polinevritis, polinevropatija, retrobulbarni nevritis, sinkopa neznana pogostnost
M-M-RVAXPRO is available in packs of 1, 10 and 20, with or without needles. 
Cepivo M-M-RVAXPRO je na voljo v pakiranjih po 1, 10 in 20 z iglami ali brez.
Gently agitate to dissolve completely. 
Rahlo stresajte, da se vsebina popolnoma raztopi.
Published clinical data support concomitant administration of the previous formulation of the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc. with other childhood vaccinations, including DTaP (or DTwP), IPV (or OPV), HIB (Haemophilus influenzae type b), HIB-HBV (Haemophilus influenzae type b with Hepatitis B vaccine), and VAR (varicella). 
Objavljeni klinični podatki podpirajo sočasno cepljenje s prejšnjo obliko cepiva proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc. in z drugimi otroškimi cepivi, vključno z DTaP (ali DTwP), IPV (ali OPV), HIB (Haemophilus influenzae tipa b), HIB-HBV (cepivo proti Haemophilus influenzae tipa b in hepatitisu B) ter VAR (norice).
Measles (titre ≥255 mIU/mL) 
Ošpice (titer ≥255 mi.e./ml)
For vaccines that cannot be given at the same time, M-M-RVAXPRO should be given 1 month before or after administration of those vaccines. 
Pri cepivih, ki se ne smejo uporabljati hkrati s cepivom M-M-RVAXPRO, je treba cepljenje s cepivom M-M-RVAXPRO opraviti 1 mesec pred ali 1 mesec po cepljenju s temi cepivi.
Additionally, other adverse reactions reported with post-marketing use of M-M-RVAXPRO and/or in clinical studies and post-marketing use of previous formulations of monovalent and of the combined measles, mumps, and rubella vaccines manufactured by Merck & Co., Inc. without regard to causality or frequency are available and are summarised in section b. The frequency of these adverse events is qualified as "not known" when it cannot be estimated based on the available data. 
Dodatno so na voljo podatki o neželenih učinkih iz obdobja trženja cepiva M-M-RVAXPRO in/ali iz kliničnih študij in iz obdobja trženja prejšnjih oblik enovalentnih in kombiniranih cepiv proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc. in so ne glede na vzročnost ali pogostnost pojavljanja povzeti v poglavju b. Pogostnost teh neželenih učinkov je opredeljena kot "neznana", ko pogostnosti iz razpoložljivih podatkov ni mogoče oceniti.
*These side effects were reported with the use of M-M-RVAXPRO or with the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc., or with its monovalent (single) components, during post-marketing use and/or during clinical studies. 
*O teh neželenih učinkih so poročali pri uporabi cepiva M-M-RVAXPRO ali cepiva proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc. ali pri cepljenju z enovalentnimi (posameznimi) komponentami tega cepiva v obdobju trženja zdravila in/ali v kliničnih študijah.
After vaccination with M-M-RVAXPRO, IG should not be given for 1 month, unless your doctor tells you otherwise. 
Po cepljenju s cepivom M-M-RVAXPRO cepljena oseba 1 mesec ne sme dobiti imunoglobulinov, razen če se zdravnik ne odloči drugače.
The powder is a light yellow compact crystalline cake. 
Prašek je svetlo rumen kompakten kristalni skupek.
The vaccine is to be injected intramuscularly (IM) or subcutaneously (SC). 
Cepivo je treba injicirati intramuskularno (i.m.)
Arthralgia and/or arthritis 
† in/ali artralgija
However, since M-M-RVAXPRO has been shown to have safety and immunogenicity profiles similar to the previous formulation of the combined measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc., experience with this vaccine can be considered. 
Ker pa se je pokazalo, da ima cepivo M-M-RVAXPRO podoben profil varnosti in imunogenosti kot prejšnja oblika kombiniranega cepiva proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc., lahko upoštevamo izkušnje s tem cepivom.
Do not use the reconstituted vaccine if you notice any particulate matter or if the appearance of the solvent or powder or of the reconstituted vaccine differs from that described above. 
Pripravljenega cepiva ne uporabite, če v njem opazite delce ali če se videz vehikla ali praška ali pripravljenega cepiva razlikuje od zgornjega opisa.
Vaccination with M-M-RVAXPRO may not result in protection in all vaccinees. 
S cepljenjem s cepivom M-M-RVAXPRO lahko ne dosežemo zaščite vseh cepljenih oseb.
- If you or your child have a family history of congenital or hereditary immunodeficiency, unless the immune competence of you or your child is demonstrated. 
- Če imate vi ali vaš otrok v družini prirojeno ali dedno imunsko pomanjkljivost, razen če imate vi ali vaš otrok dokazano imunsko zmožnost.
The potential risk-to-benefit ratio should be carefully evaluated before considering vaccination in such cases (see section 4.8). 
V takšnih primerih je treba pred odločitvijo za cepljenje skrbno ovrednotiti razmerje med morebitnim tveganjem in koristjo cepljenja (glejte poglavje 4.8).